State Farm Mutual Automobile Insurance Co. increased its stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 153.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,746,790 shares of the medical instruments supplier's stock after acquiring an additional 9,521,730 shares during the period. State Farm Mutual Automobile Insurance Co. owned about 3.04% of Baxter International worth $377,923,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in BAX. BlackRock Inc. bought a new position in Baxter International during the 2nd quarter worth about $1,744,874,000. Pzena Investment Management LLC acquired a new stake in shares of Baxter International in the 2nd quarter valued at about $1,392,098,000. Equity Investment Corp bought a new stake in shares of Baxter International in the second quarter valued at about $146,815,000. Bank of America Corp DE bought a new stake in shares of Baxter International in the second quarter valued at about $132,993,000. Finally, Aberdeen Group plc lifted its holdings in shares of Baxter International by 16,776.9% in the third quarter. Aberdeen Group plc now owns 3,743,975 shares of the medical instruments supplier's stock valued at $89,855,000 after purchasing an additional 3,721,791 shares in the last quarter. 90.19% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on BAX. Wells Fargo & Company upped their price objective on Baxter International from $23.00 to $25.00 and gave the stock an "equal weight" rating in a research report on Friday, October 30th. Jefferies Financial Group reissued a "hold" rating and issued a $25.00 target price on shares of Baxter International in a research report on Thursday, October 29th. Stifel Nicolaus boosted their target price on Baxter International from $19.00 to $24.00 and gave the company a "hold" rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. cut their target price on Baxter International from $26.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, October 30th. Finally, Zacks Research raised Baxter International from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $23.27.
Get Our Latest Stock Analysis on Baxter International
Baxter International Stock Down 0.0%
BAX stock opened at $25.38 on Friday. The company has a market cap of $13.13 billion, a price-to-earnings ratio of -18.00, a P/E/G ratio of 3.73 and a beta of 0.68. Baxter International Inc. has a twelve month low of $15.73 and a twelve month high of $30.00. The business has a 50 day moving average price of $24.64 and a two-hundred day moving average price of $21.81. The company has a quick ratio of 1.19, a current ratio of 1.79 and a debt-to-equity ratio of 1.20.
Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. The company had revenue of $2.98 billion for the quarter, compared to analysts' expectations of $2.91 billion. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. The business's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 EPS. Analysts anticipate that Baxter International Inc. will post 2.10 EPS for the current fiscal year.
Baxter International Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, November 27th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, November 27th. Baxter International's payout ratio is presently -2.84%.
More Baxter International News
Investors following BAX have been watching these news items:
- Positive Sentiment: Zacks raised its FY2026, FY2027 and FY2028 EPS forecasts to $2.09, $2.02 and $2.15, respectively. It also increased estimates for Q3 and Q4 2027 and Q3 2028, signaling improved expectations for some periods. MarketBeat report
- Neutral Sentiment: The revisions were mixed overall, and Zacks kept its Hold rating. The adjustments are analyst forecasts rather than a change in Baxter’s business outlook or formal company guidance. MarketBeat report
- Negative Sentiment: Zacks lowered its EPS estimates for Q4 2026, Q1 and Q2 2027, and Q2 2028. These cuts suggest softer expectations in several nearer-term periods and offset some of the upward revisions. MarketBeat report
Baxter International Profile
(
Free Report)
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.